888-969-2592
Kalkine 0
countryflagCA

Arcus Biosciences Inc

Healthcare US RCUS

8.29USD
-0.24(2.81%)

Last update at 2025-05-09T16:52:00Z

Day Range

8.268.88
LowHigh

52 Week Range

12.9525.47
LowHigh

Fundamentals

  • Previous Close 8.53
  • Market Cap1358.63M
  • Volume370939
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-317.00000M
  • Revenue TTM120.00M
  • Revenue Per Share TTM1.64
  • Gross Profit TTM -176.00000M
  • Diluted EPS TTM-4.0

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -266.00000M 54.65M -122.85800M -84.71000M -49.59400M
Minority interest - - - - -
Net income -267.00000M 52.83M -116.67700M -75.93100M -49.59400M
Selling general administrative 104.00M 72.29M 42.40M 25.23M 13.57M
Selling and marketing expenses - - - - -
Gross profit 112.00M 382.88M 77.52M 15.00M 8.35M
Reconciled depreciation 6.00M 3.84M 4.19M 3.58M 3.66M
Ebit -280.00000M 54.25M -124.23500M -92.28700M -59.75200M
Ebitda -264.00000M 54.91M -124.84800M -88.70900M -56.08800M
Depreciation and amortization 16.00M 0.66M -0.61300M 3.58M 3.66M
Non operating income net other - 0.40M 1.38M 4.00M 5.26M
Operating income -280.00000M 54.25M -124.23500M -88.70900M -54.85900M
Other operating expenses 392.00M 328.63M 201.75M 103.71M 63.21M
Interest expense 2.00M 0.26M 0.00000M 0.00000M 4.92M
Tax provision 1.00M 1.81M - - -
Interest income 16.00M 0.66M 1.38M 5.20M 4.92M
Net interest income 14.00M 0.40M 1.38M 5.20M 4.92M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.00M 1.81M -6.18100M -8.77900M 5.26M
Total revenue 112.00M 382.88M 77.52M 15.00M 8.35M
Total operating expenses 392.00M 328.63M 201.75M 103.71M 63.21M
Cost of revenue - - - - 49.65M
Total other income expense net 14.00M 0.40M 1.38M 4.00M 0.34M
Discontinued operations - - - - -
Net income from continuing ops -267.00000M 52.83M -122.85800M -84.71000M -49.59400M
Net income applicable to common shares -267.00000M 52.83M -122.85800M -84.71000M -49.59400M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 1345.00M 1591.90M 772.29M 203.11M 274.93M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 58.00M 15.62M 5.47M 4.30M 2.32M
Total liab 688.00M 750.45M 269.99M 39.27M 39.98M
Total stockholder equity 657.00M 841.45M 502.30M 163.84M 234.94M
Deferred long term liab 3.00M 4.00M 3.20M 15.76M 21.26M
Other current liab 76.00M 0.05M 3.57M 1.48M 1.56M
Common stock 1206.00M 0.00700M 0.00600M 0.00400M 0.00400M
Capital stock 1206.00M 0.00700M 0.00600M 0.00400M 0.00400M
Retained earnings -542.00000M -275.35400M -328.18400M -205.32600M -122.82800M
Other liab 378.00M 467.48M 133.08M 16.56M 23.05M
Good will - - - - -
Other assets 14.00M 10.73M 25.67M 1.07M 0.49M
Cash 206.00M 147.91M 173.41M 57.94M 71.06M
Cash and equivalents - - - - -
Total current liabilities 193.00M 166.08M 121.67M 22.71M 16.93M
Current deferred revenue 97.00M 102.00M 74.57M 7.00M 6.25M
Net debt -206.00000M -31.02700M -158.17200M -57.93700M -71.06400M
Short term debt - 53.77M 27.85M 9.52M 6.02M
Short long term debt - - - - -
Short long term debt total - 116.89M 15.24M - -
Other stockholder equity -7.00000M 1118.06M 830.44M 369.10M 82.95M
Property plant equipment 135.00M 32.45M 10.81M 9.33M 11.11M
Total current assets 1067.00M 681.30M 735.09M 192.71M 258.95M
Long term investments 129.00M 181.99M 6.44M 0.00000M 4.38M
Net tangible assets 657.00M 841.45M 502.30M 163.84M 234.94M
Short term investments 803.00M 351.39M 555.23M 130.33M 185.48M
Net receivables 43.00M 746.82M 1.70M 0.13M 0.08M
Long term debt - - - - -
Inventory -172.00000M -762.44200M -7.16900M - -
Accounts payable 20.00M 10.26M 15.68M 4.70M 3.10M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -7.00000M -1.26100M 0.04M 0.06M -0.10700M
Additional paid in capital - - - - -
Common stock total equity - 0.00700M 0.00600M 0.00400M 0.00400M
Preferred stock total equity - - - - -
Retained earnings total equity - -275.35400M -328.18400M -205.32600M -122.82800M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 114.00M 591.19M 7.18M 1.07M 0.49M
Deferred long term asset charges - - - - -
Non current assets total 278.00M 910.60M 37.21M 10.40M 15.98M
Capital lease obligations - 116.89M 15.24M - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -413.00000M -28.79100M -431.31200M 61.14M -109.69700M
Change to liabilities -104.00000M 4.87M 24.07M 3.28M 3.12M
Total cashflows from investing activities -413.00000M -3.86800M -434.36700M 59.21M -113.44000M
Net borrowings - - - - -
Total cash from financing activities 33.00M 237.34M 438.68M 1.12M 129.07M
Change to operating activities 23.00M 14.09M 21.32M 0.53M 1.75M
Net income -267.00000M 52.83M -122.85800M -84.71000M -49.59400M
Change in cash 58.00M -22.69900M 115.48M -13.12700M -27.36200M
Begin period cash flow 151.00M 173.62M 58.14M 71.27M 98.43M
End period cash flow 209.00M 150.92M 173.62M 58.14M 71.06M
Total cash from operating activities 438.00M -256.17100M 111.17M -73.46200M -42.99600M
Issuance of capital stock 23.00M 220.24M 433.78M 1.22M 125.11M
Depreciation 6.00M 3.84M 4.19M 3.58M 3.66M
Other cashflows from investing activities 3.00M 51.00M 3.00M 61.14M -109.69700M
Dividends paid - - - - -
Change to inventory - 14.09M 21.32M 1.07M -
Change to account receivables 704.00M -17.04600M -0.91700M -0.13200M -0.13200M
Sale purchase of stock - -0.00600M -0.05400M 1.12M 124.98M
Other cashflows from financing activities 10.00M 17.11M 4.95M -0.09400M 3.96M
Change to netincome 76.00M 54.53M 21.82M 10.18M 3.35M
Capital expenditures 12.00M 26.08M 3.06M 1.93M 3.74M
Change receivables - - - 0.08M -0.05800M
Cash flows other operating - -377.01100M 185.03M -3.24000M -1.72800M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -22.69900M 115.48M -13.12700M -27.36200M
Change in working capital 623.00M -375.61800M 208.06M 0.12M 1.33M
Stock based compensation 65.00M 54.53M 21.82M 8.98M 3.87M
Other non cash items 11.00M 3.47M -0.04600M -1.43600M -0.17700M
Free cash flow 426.00M -282.24900M 108.11M -75.38700M -46.73900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RCUS
Arcus Biosciences Inc		 -0.24 2.81% 8.29 - - 10.66 2.46 4.08 -1.7537
NVO
Novo Nordisk A/S		 1.41 2.17% 66.26 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 2.59 4.06% 66.40 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.70 0.40% 431.30 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -10.605 1.94% 537.07 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT investigational monoclonal antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Arcus Biosciences Inc

3928 Point Eden Way, Hayward, CA, United States, 94545

Key Executives

Name Title Year Born
Dr. Terry J. Rosen Ph.D. Co-Founder, Chairman & CEO 1960
Dr. Juan Carlos Jaen Ph.D. Co-Founder, Pres & Director 1958
Mr. Robert C. Goeltz II Principal Financial & Accounting Officer and CFO 1973
Ms. Jennifer A. Jarrett M.B.A. COO & Director 1971
Ms. Carolyn C. Tang J.D. Gen. Counsel & Corp. Sec. 1979
Dr. K. Christopher Garcia Ph.D. Co-Founder & Member of Scientific Advisory Board NA
Dr. Stephen Young Ph.D. Sr. VP of Technology & Quantitative Biology 1969
Dr. Jonathan Yingling Ph.D. Chief Scientific Officer 1969
Ms. Katherine Bock VP of Investor Relations & Corp. Strategy NA
Holli Kolkey VP of Corp. Communications NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.